Vertex Pharmaceuticals Incorporated (VRTX) Stock Price Today
Aura AI Summary
Key Stats
- $132.01BMarket Cap
- 1,152,211Volume
- HealthSector
- $559.4152W High
- $423.2452W Low
- 125 DaysTypical Hold Time
- $132.18BEnterprise Value
- -Div Yield
- 71% Sell | 29% BuyTrading Activity
Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $423.24 and a high of $559.41, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Most Recent News
LEPAS L8 PHEV launches in the Gulf, offering premium electric SUV with advanced features and local climate adaptation.
LEPAS, Chery Auto's premium new energy vehicle brand, has launched its LEPAS L8 PHEV in the Gulf region, starting sales in the UAE with plans for Kuwait, Qatar, and others. The SUV combines elegant design inspired by a leopard, advanced smart driving...

S&P 500 falls 3.7% into correction amid AI sector turmoil and Nvidia leadership crisis
The S&P 500 dropped 3.7% on Friday, entering correction territory after an 8.6% weekly decline driven by worries over the AI sector and Nvidia's leadership crisis. Investors are concerned about rising interest rates, regulatory scrutiny, and the impa...

Amazon stock shows no consistent rally after AWS re:Invent conferences, despite strong AWS growth.
Amazon's AWS re:Invent conference runs Nov. 30-Dec. 4, but the stock has only outperformed the S&P 500 in 4 of the last 10 post-conference months. AWS sales grew 39% year over year in Q3 2026, driving most of Amazon's profit, yet the stock's price mo...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.